Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

  • STATUS
    Not Recruiting
  • End date
    Oct 13, 2021
  • participants needed
    800
  • sponsor
    EirGenix, Inc.
Updated on 24 January 2021
estrogen
carcinoma
progesterone
HER2
adjuvant therapy
progesterone receptor
estrogen receptor
herceptin
invasive breast cancer
mastectomy
lumpectomy
immunostimulant
female breast cancer
invasive carcinoma

Summary

The purpose of this research study is to compare the efficacy and safety of EG12014 with Herceptin as neoadjuvant treatment for 12 weeks, followed by surgery and subsequent EG12014 or Herceptin adjuvant treatment for up to 12 months.

Details
Condition Breast Cancer
Treatment Herceptin, EG12014
Clinical Study IdentifierNCT03433313
SponsorEirGenix, Inc.
Last Modified on24 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note